ClinicalTrials.gg
CompletedNCT01272908Updated Aug 15, 2017Results posted

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)

A Phase 3 interventional study of rituximab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 41 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 5 months after the study started (first participant enrolled Jul 2006, registered Jan 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
37th of 63
120 · median 159
Started
2006
with 10 others
Phase 3
27 of 63
1 open now
Registered
30th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 37th largest by enrollment, is one of 11 that started in 2006, is one of 27 in phase 3, and was the 30th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior anti-TNF therapy. All patients will receive MabThera 1000 mg as an intravenous infusion on days 1 and 15. After the initial study phase of 24 weeks, eligible patients may receive one re-treatment with MabThera. The anticipated time on study treatment is 48 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, 18-80 years of age
  • Moderate to severe active rheumatoid arthritis
  • Inadequate response to a single previous or current treatment with an anti-TNF agent
  • Methotrexate for at least 12 weeks, at a stable dose over the past 4 weeks

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with MabThera
  • Use of an anti-TNF agent within past 8 weeks (4 in the case of etanercept)
  • Concurrent treatment with any Disease Modifying Anti-Rheumatic Drug (DMARD) other than methotrexate
  • Active infection, or history of serious or chronic infection
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Single arm

    Drug: rituximab

Interventions

  • 1000 mg intravenously on Days 1 and 15

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events During the Initial Treatment Period - Overall Summary

    Percentage of participants who reported an AE or serious AE (SAE), a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.

    Time frame: Days 1, 2, 15, and 16 and Week 48 of Initial treatment period

Secondary outcomes

  1. Percentage of Participants With Adverse Events During the Re-Treatment Period - Overall Summary

    Percentage of participants who reported an AE or SAE, a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.

    Time frame: Days 1, 2, 15, and 16 and Week 48 of Re-treatment period

  2. Percentage of Participants Meeting American College of Rheumatology (ACR) Response Criteria During the Initial Treatment Period

    ACR20/50/70, defined as ≥20 percent (%), 50%, or 70% improvement, respectively, compared to baseline in tender joint count (TJC) and swollen joint count (SJC), and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and an acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-Reactive Protein \[CRP\]). If CRP was missing or not done, then ESR was used.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  3. Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Initial Treatment Period

    Complete clinical response was defined as having an ACR70 for at least 13 weeks.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  4. Percentage of Participants Meeting ACR Response Criteria During the Re-treatment Period

    ACR20/50/70, defined as ≥20%, 50%, or 70% improvement, respectively, compared to baseline in TJC and SJC, and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; HAQ-DI; and an acute phase reactant (ESR or CRP). If CRP was missing or not done, then ESR was used.

    Time frame: Weeks 12 and 24 of Re-treatment period

  5. Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Re-Treatment Period

    Complete clinical response was defined as having an ACR70 for at least 13 weeks.

    Time frame: Weeks 12 and 24 of Re-treatment period

  6. Percentage of Participants Meeting European League Against Rheumatism (EULAR) Response Criteria During the Initial Treatment Period

    The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score less than or equal to \[≤\]3.2), moderate (DAS28 score greater than \[\>\]3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  7. Percentage of Participants Meeting EULAR Response Criteria During the Re-Treatment Period

    The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria.

    Time frame: Weeks 12 and 24 of Re-treatment period

  8. Change From Baseline in DAS28 During the Initial Treatment Period

    The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  9. Change From Baseline in DAS28 During the Re-Treatment Period

    The DAS28 scoring used 4 core components: SJC, TJC, Patient Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.

    Time frame: Weeks 12 and 24 of Re-treatment period

  10. Change From Baseline in SJC During the Initial Treatment Period

    Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  11. Change From Baseline in SJC During the Re-Treatment Period

    Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.

    Time frame: Weeks 12 and 24 of Re-treatment period

  12. Change From Baseline in TJC During the Initial Treatment Period

    Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  13. Change From Baseline in TJC During the Re-Treatment Period

    Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.

    Time frame: Weeks 12 and 24 of Re-treatment period

  14. Change From Baseline in Physician's Global Assessment of Disease Activity During the Initial Treatment Period

    Physician Global Assessment of Disease Activity was measured using a 100-mm visual analog scale (VAS) where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  15. Change From Baseline in Physician's Global Assessment of Disease Activity During the Re-Treatment Period

    Physician Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.

    Time frame: Weeks 12 and 24 of Re-treatment period

  16. Change From Baseline in Patient Global Assessment of Disease Activity Score During the Initial Treatment Period

    Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  17. Change From Baseline in Patient Global Assessment of Disease Activity During the Re-Treatment Period

    Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.

    Time frame: Weeks 12 and 24 of Re-treatment period and Week 4 after last maintenance

  18. Change From Baseline in Patient Global Assessment of Pain During the Initial Treatment Period

    Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  19. Change From Baseline in Patient Global Assessment of Pain During the Re-Treatment Period

    Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.

    Time frame: Weeks 12 and 24 of Re-treatment period

  20. Change From Baseline HAQ-DI Score During the Initial Treatment Period

    HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determined the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if \> 2 categories were missing.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  21. Change From Baseline HAQ-DI Score During the Re-Treatment Period

    HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determines the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if \>2 categories were missing.

    Time frame: Weeks 12 and 24 of Re-treatment period

  22. Change From Baseline in ESR During the Initial Treatment Period

    ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  23. Change From Baseline in ESR During the Re-Treatment Period

    ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.

    Time frame: Weeks 12 and 24 of Re-treatment period

  24. Change From Baseline in CRP During the Initial Treatment Period

    CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  25. Change From Baseline CRP During the Re-Treatment Period

    CRP levels were measured in mg/L and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.

    Time frame: Weeks 12 and 24 of Re-treatment period

  26. Percentage of Participants With Disease Remission According to DAS28 in the Initial Treatment Period

    The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  27. Percentage of Participants With Disease Remission According to DAS28 in the Re-Treatment Period

    The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.

    Time frame: Weeks 12 and 24 of Re-treatment period

  28. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score During the Initial Treatment Period

    Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.

    Time frame: Weeks 4, 12, 24, 36, and 48 of Initial treatment period

  29. Change From Baseline in FACIT-F Total Score During the Re-Treatment Period

    Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.

    Time frame: Weeks 12 and 24 of Re-treatment period

07

Results

Posted Aug 5, 2014
Limitations and caveats
Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.

Participant flow

Initial Treatment Period
Participant flow — Initial Treatment Period
MilestoneRituximab + Methotrexate (MTX)
Started120
Completed112
Not completed8
Withdrew: Adverse event1
Withdrew: Lack of efficacy5
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject1
Re-Treatment Period
Participant flow — Re-Treatment Period
MilestoneRituximab + Methotrexate (MTX)
Started77
Completed71
Not completed6
Withdrew: Adverse event2
Withdrew: Lack of efficacy3
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants With Adverse Events During the Initial Treatment Period - Overall Summary

Percentage of participants who reported an AE or serious AE (SAE), a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.

Time frame:
Days 1, 2, 15, and 16 and Week 48 of Initial treatment period
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events During the Initial Treatment Period - Overall Summary
percentage of participantsInitial Treatment Period: Rituximab + MTX
With an AE85.0
With a drug-related AE41.7
With an acute infusion reaction20.8
With AE leading to study drug discontinuation4.2
With an SAE10.0
With infections47.5
With a serious infections2.5
Who died0
SecondaryPercentage of Participants With Adverse Events During the Re-Treatment Period - Overall Summary

Percentage of participants who reported an AE or SAE, a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.

Time frame:
Days 1, 2, 15, and 16 and Week 48 of Re-treatment period
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events During the Re-Treatment Period - Overall Summary
percentage of participantsRe-Treatment Period: Rituximab + MTX
With an AE68.8
With a drug-related AE27.3
With an acute infusion reaction13.0
With AE leading to study drug discontinuation1.3
With an SAE9.1
With infections27.3
With a serious infections2.6
Who died0
SecondaryPercentage of Participants Meeting American College of Rheumatology (ACR) Response Criteria During the Initial Treatment Period

ACR20/50/70, defined as ≥20 percent (%), 50%, or 70% improvement, respectively, compared to baseline in tender joint count (TJC) and swollen joint count (SJC), and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and an acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-Reactive Protein \[CRP\]). If CRP was missing or not done, then ESR was used.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Number · percentage of participants
Percentage of Participants Meeting American College of Rheumatology (ACR) Response Criteria During the Initial Treatment Period
percentage of participantsInitial Treatment Period: Rituximab + MTX
ACR20, Week 431.7
ACR20, Week 1250.0
ACR20, Week 2454.2
ACR20, Week 3625.0
ACR20, Week 4815.8
ACR50, Week 45.8
ACR50, Week 1222.5
ACR50, Week 2425.0
ACR50, Week 3611.7
ACR50, Week 489.2
ACR70, Week 40
ACR70, Week 124.2
ACR70, Week 245.8
ACR70, Week 365.8
ACR70, Week 484.2
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · Regression, Logistic · p = 0.253 · Odds ratio (or): 2.293
  • Initial Treatment Period: Rituximab + MTX · Regression, Logistic · p = 0.005 · Odds ratio (or): 3.019
  • Initial Treatment Period: Rituximab + MTX · Regression, Logistic · p = 0.023 · Odds ratio (or): 5.552
  • Initial Treatment Period: Rituximab + MTX · Regression, Logistic · p = 0.001 · Odds ratio (or): 6.861
SecondaryPercentage of Participants With Complete Clinical Response Per ACR Criteria During the Initial Treatment Period

Complete clinical response was defined as having an ACR70 for at least 13 weeks.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Initial Treatment Period
percentage of participantsInitial Treatment Period: Rituximab + MTX
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Initial Treatment Period4.2
SecondaryPercentage of Participants Meeting ACR Response Criteria During the Re-treatment Period

ACR20/50/70, defined as ≥20%, 50%, or 70% improvement, respectively, compared to baseline in TJC and SJC, and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; HAQ-DI; and an acute phase reactant (ESR or CRP). If CRP was missing or not done, then ESR was used.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Number · percentage of participants
Percentage of Participants Meeting ACR Response Criteria During the Re-treatment Period
percentage of participantsRe-Treatment Period: Rituximab + MTX
ACR20, Week 1254.5
ACR20, Week 2458.4
ACR50, Week 1226.0
ACR50, Week 2428.6
ACR70, Week 126.5
ACR70, Week 249.1
SecondaryPercentage of Participants With Complete Clinical Response Per ACR Criteria During the Re-Treatment Period

Complete clinical response was defined as having an ACR70 for at least 13 weeks.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Re-Treatment Period
percentage of participantsRe-Treatment Period: Rituximab + MTX
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Re-Treatment Period1.3
SecondaryPercentage of Participants Meeting European League Against Rheumatism (EULAR) Response Criteria During the Initial Treatment Period

The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score less than or equal to \[≤\]3.2), moderate (DAS28 score greater than \[\>\]3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Number · percentage of participants
Percentage of Participants Meeting European League Against Rheumatism (EULAR) Response Criteria During the Initial Treatment Period
percentage of participantsInitial Treatment Period: Rituximab + MTX
Week 4: Good4.2
Week 4: Moderate47.5
Week 4: Good/Moderate51.7
Week 4: None46.7
Week 12: Good9.2
Week 12: Moderate55.0
Week 12: Good/Moderate64.2
Week 12: None33.3
Week 24: Good17.5
Week 24: Moderate50.0
Week 24: Good/Moderate67.5
Week 24: None26.7
Week 36: Good10.8
Week 36: Moderate24.2
Week 36: Good/Moderate35.0
Week 36: None23.3
Week 48: Good8.3
Week 48: Moderate10.8
Week 48: Good/Moderate19.2
Week 48: None10.0
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · Regression, Logistic · p = 0.667 · Odds ratio (or): 2.099
  • Initial Treatment Period: Rituximab + MTX · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.589
  • Initial Treatment Period: Rituximab + MTX · Regression, Logistic · p = 0.440 · Odds ratio (or): 2.138
  • Initial Treatment Period: Rituximab + MTX · Regression, Logistic · p = 0.012 · Odds ratio (or): 3.009
SecondaryPercentage of Participants Meeting EULAR Response Criteria During the Re-Treatment Period

The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Number · percentage of participants
Percentage of Participants Meeting EULAR Response Criteria During the Re-Treatment Period
percentage of participantsRe-Treatment Period: Rituximab + MTX
Week 12: Good20.8
Week 12: Moderate53.2
Week 12: Good/Moderate74.0
Week 12: None22.1
Week 24: Good19.5
Week 24: Moderate48.1
Week 24: Good/Moderate67.5
Week 24: None26.0
SecondaryChange From Baseline in DAS28 During the Initial Treatment Period

The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Mean · scores on a scale
Change From Baseline in DAS28 During the Initial Treatment Period
scores on a scaleInitial Treatment Period: Rituximab + MTX
Baseline (n=117)6.4 ± 1.1
Change at Week 4 (n=112)-1.1 ± 0.8
Change at Week 12 (n=108)-1.7 ± 1.2
Change at Week 24 (n=105)-2.0 ± 1.2
Change at Week 36 (n=66)-1.7 ± 1.7
Change at Week 48 (n=33)-2.1 ± 1.6
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · t-test, 1 sided · p = <0.001
  • Initial Treatment Period: Rituximab + MTX · t-test, 1 sided · p = <0.001
  • Initial Treatment Period: Rituximab + MTX · t-test, 1 sided · p = <0.001
  • Initial Treatment Period: Rituximab + MTX · t-test, 1 sided · p = <0.001
  • Initial Treatment Period: Rituximab + MTX · t-test, 1 sided · p = <0.001
SecondaryChange From Baseline in DAS28 During the Re-Treatment Period

The DAS28 scoring used 4 core components: SJC, TJC, Patient Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score \<2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Mean · scores on a scale
Change From Baseline in DAS28 During the Re-Treatment Period
scores on a scaleRe-Treatment Period: Rituximab + MTX
Baseline (n=117)6.4 ± 1.1
Change at Week 12 (n=70)-2.3 ± 1.3
Change at Week 24 (n=65)-2.2 ± 1.4
SecondaryChange From Baseline in SJC During the Initial Treatment Period

Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Mean · swollen joints
Change From Baseline in SJC During the Initial Treatment Period
swollen jointsInitial Treatment Period: Rituximab + MTX
Baseline (n=117)13.7 ± 5.33
Change at Week 4 (n=115)-3.6 ± 4.45
Change at Week 12 (n=113)-5.7 ± 4.97
Change at Week 24 (n=106)-7.1 ± 5.66
Change at Week 36 (n=67)-5.6 ± 6.50
Change at Week 48 (n=33)-7.7 ± 5.56
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · Wilcoxon Signed-Rank test · p = <0.001
SecondaryChange From Baseline in SJC During the Re-Treatment Period

Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Mean · swollen joints
Change From Baseline in SJC During the Re-Treatment Period
swollen jointsInitial Treatment Period: Rituximab + MTX
Baseline (n=117)13.7 ± 5.33
Change at Week 12 (n=71)-7.6 ± 6.07
Change at Week 24 (n=69)-7.7 ± 5.43
SecondaryChange From Baseline in TJC During the Initial Treatment Period

Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Mean · tender joints
Change From Baseline in TJC During the Initial Treatment Period
tender jointsInitial Treatment Period: Rituximab + MTX
Baseline (n=117)16.1 ± 6.62
Change at Week 4 (n=115)-6.3 ± 5.95
Change at Week 12 (n=113)-7.8 ± 6.68
Change at Week 24 (n=106)-9.0 ± 6.42
Change at Week 36 (n=67)-7.4 ± 8.35
Change at Week 48 (n=33)-7.8 ± 8.31
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · t-test, 1 sided · p = <0.001
SecondaryChange From Baseline in TJC During the Re-Treatment Period

Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Mean · tender joints
Change From Baseline in TJC During the Re-Treatment Period
tender jointsRe-Treatment Period: Rituximab + MTX
Baseline (n=117)16.1 ± 6.62
Change at Week 12 (n=71)-9.4 ± 7.54
Change at Week 24 (n=69)-9.7 ± 6.92
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity During the Initial Treatment Period

Physician Global Assessment of Disease Activity was measured using a 100-mm visual analog scale (VAS) where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Mean · mm
Change From Baseline in Physician's Global Assessment of Disease Activity During the Initial Treatment Period
mmInitial Treatment Period: Rituximab + MTX
Baseline (n=120)68.6 ± 17.34
Change at Week 4 (n=117)-22.0 ± 21.67
Change at Week 12 (n=116)-31.4 ± 24.28
Change at Week 24 (n=109)-35.1 ± 24.45
Change at Week 36 (n=68)-28.6 ± 28.68
Change at Week 48 (n=34)-35.9 ± 25.18
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · t-test, 1 sided · p = <0.001
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity During the Re-Treatment Period

Physician Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Mean · mm
Change From Baseline in Physician's Global Assessment of Disease Activity During the Re-Treatment Period
mmRe-Treatment Period: Rituximab + MTX
Baseline (n=120)68.6 ± 17.34
Change at Week 12 (n=73)-35.5 ± 25.95
Change at Week 24 (n=69)-41.5 ± 24.43
SecondaryChange From Baseline in Patient Global Assessment of Disease Activity Score During the Initial Treatment Period

Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Disease Activity Score During the Initial Treatment Period
mmInitial Treatment Period: Rituximab + MTX
Baseline (n=120)67.5 ± 22.73
Change at Week 4 (n=117)-19.7 ± 21.50
Change at Week 12 (n=116)-26.3 ± 26.84
Change at Week 24 (n=109)-29.2 ± 25.72
Change at Week 36 (n=68)-23.8 ± 30.42
Change at Week 48 (n=34)-28.5 ± 22.92
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · Wilcoxon Signed Rank test · p = <0.001
SecondaryChange From Baseline in Patient Global Assessment of Disease Activity During the Re-Treatment Period

Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.

Time frame:
Weeks 12 and 24 of Re-treatment period and Week 4 after last maintenance
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Disease Activity During the Re-Treatment Period
mmRe-Treatment Period: Rituximab + MTX
Baseline (n=120)67.5 ± 22.73
Change at Week 12 (n=72)-32.6 ± 29.20
Change at Week 24 (n=72)-30.7 ± 28.70
SecondaryChange From Baseline in Patient Global Assessment of Pain During the Initial Treatment Period

Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Pain During the Initial Treatment Period
mmInitial Treatment Period: Rituximab + MTX
Baseline (n=120)60.2 ± 22.85
Change at Week 4 (n=117)-17.5 ± 21.80
Change at Week 12 (n=113)-24.0 ± 25.31
Change at Week 24 (n=108)-25.7 ± 25.40
Change at Week 36 (n=68)-18.0 ± 29.18
Change at Week 48 (n=33)-22.6 ± 20.07
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · t-test, 1 sided · p = <0.001
SecondaryChange From Baseline in Patient Global Assessment of Pain During the Re-Treatment Period

Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Pain During the Re-Treatment Period
mmRe-Treatment Period: Rituximab + MTX
Baseline (n=120)60.2 ± 22.85
Change at Week 12 (n=72)-28.3 ± 28.02
Change at Week 24 (n=72)-26.6 ± 27.61
SecondaryChange From Baseline HAQ-DI Score During the Initial Treatment Period

HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determined the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if \> 2 categories were missing.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Mean · scores on a scale
Change From Baseline HAQ-DI Score During the Initial Treatment Period
scores on a scaleInitial Treatment Period: Rituximab + MTX
Baseline (n=120)1.7 ± 0.57
Change at Week 4 (n=117)-0.2 ± 0.36
Change at Week 12 (n=116)-0.3 ± 0.46
Change at Week 24 (n=108)-0.4 ± 0.48
Change at Week 36 (n=68)-0.3 ± 0.53
Change at Week 48 (n=34)-0.4 ± 0.56
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · Wilcoxon Signed Rank test · p = <0.001
SecondaryChange From Baseline HAQ-DI Score During the Re-Treatment Period

HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determines the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if \>2 categories were missing.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Mean · scores on a scale
Change From Baseline HAQ-DI Score During the Re-Treatment Period
scores on a scaleRe-Treatment Period: Rituximab + MTX
Baseline (n=120)1.7 ± 0.57
Change at Week 12 (n=73)-0.5 ± 0.60
Change at Week 24 (n=72)-0.5 ± 0.62
SecondaryChange From Baseline in ESR During the Initial Treatment Period

ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Mean · mm/hr
Change From Baseline in ESR During the Initial Treatment Period
mm/hrInitial Treatment Period: Rituximab + MTX
Baseline (n=120)37.0 ± 27.84
Change at Week 4 (n=112)-4.5 ± 13.57
Change at Week 12 (n=112)-11.3 ± 20.60
Change at Week 24 (n=107)-16.0 ± 20.36
Change at Week 36 (n=68)-9.2 ± 22.29
Change at Week 48 (n=34)-12.0 ± 17.93
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · Wilcoxon Signed Rank test · p = <0.001
SecondaryChange From Baseline in ESR During the Re-Treatment Period

ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Mean · mm/hr
Change From Baseline in ESR During the Re-Treatment Period
mm/hrRe-Treatment Period: Rituximab + MTX
Baseline (n=120)37.0 ± 27.84
Change at Week 12 (n=73)-17.9 ± 22.07
Change at Week 24 (n=67)-18.7 ± 23.05
SecondaryChange From Baseline in CRP During the Initial Treatment Period

CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Mean · mg/L
Change From Baseline in CRP During the Initial Treatment Period
mg/LInitial Treatment Period: Rituximab + MTX
Baseline (n=119)25.6 ± 28.87
Change at Week 4 (n=110)-7.9 ± 17.44
Change at Week 12 (n=113)-11.9 ± 31.97
Change at Week 24 (n=108)-16.1 ± 24.82
Change at Week 36 (n=67)-9.1 ± 25.74
Change at Week 48 (n=34)-7.6 ± 27.06
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · Wilcoxon Signed Rank test · p = <0.001
SecondaryChange From Baseline CRP During the Re-Treatment Period

CRP levels were measured in mg/L and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Mean · mg/L
Change From Baseline CRP During the Re-Treatment Period
mg/LRe-Treatment Period: Rituximab + MTX
Baseline (n=119)25.6 ± 28.87
Change at Week 12 (n=70)-16.9 ± 27.15
Change at Week 24 (n=67)-15.3 ± 26.62
SecondaryPercentage of Participants With Disease Remission According to DAS28 in the Initial Treatment Period

The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Remission According to DAS28 in the Initial Treatment Period
percentage of participantsInitial Treatment Period: Rituximab + MTX
Week 40.8
Week 125.0
Week 245.8
Week 365.8
Week 485.8
SecondaryPercentage of Participants With Disease Remission According to DAS28 in the Re-Treatment Period

The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score \>3.2 but ≤5.1), or high (DAS28 score \>5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Remission According to DAS28 in the Re-Treatment Period
percentage of participantsRe-Treatment Period: Rituximab + MTX
Week 125.0
Week 244.2
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score During the Initial Treatment Period

Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.

Time frame:
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Reported as:
Mean · scores on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score During the Initial Treatment Period
scores on a scaleInitial Treatment Period: Rituximab + MTX
Baseline (n=120)28.9 ± 10.22
Change at Week 4 (n=116)-5.4 ± 8.19
Change at Week 12 (n=116)-7.3 ± 10.38
Change at Week 24 (n=108)-9.1 ± 9.90
Change at Week 36 (n=68)-8.6 ± 11.71
Change at Week 48 (n=34)-10.9 ± 10.68
Statistical analysis
  • Initial Treatment Period: Rituximab + MTX · t-test, 1 sided · p = <0.001
  • Initial Treatment Period: Rituximab + MTX · Wilcoxon Signed Rank test · p = <0.001
SecondaryChange From Baseline in FACIT-F Total Score During the Re-Treatment Period

Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.

Time frame:
Weeks 12 and 24 of Re-treatment period
Reported as:
Mean · scores on a scale
Change From Baseline in FACIT-F Total Score During the Re-Treatment Period
scores on a scaleRe-Treatment Period: Rituximab + MTX
Baseline (n=120)28.9 ± 10.22
Change at Week 12 (n=73)-8.3 ± 12.64
Change at Week 24 (n=72)-8.9 ± 11.72

Adverse events

Collected over Reporting period began after written informed consent was obtained and ended 48 weeks after therapy was initiated or 24 weeks after re-treatment had occurred.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial Treatment: Rituximab + MTX—12/120 (10%)102/120 (85%)
Re-treatment: Rituximab + MTX—7/77 (9.1%)53/77 (68.8%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventInitial Treatment: Rituximab + MTXRe-treatment: Rituximab + MTX
Hip fractureInjury, poisoning and procedural complications2/1200/77
Urinary tract infectionInfections and infestations1/1201/77
Breast cellulitisInfections and infestations0/1201/77
Ovarian epithelial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1201/77
Upper limb fractureInjury, poisoning and procedural complications0/1201/77
Large intestine perforationGastrointestinal disorders0/1201/77
HeadacheNervous system disorders0/1201/77
Vision blurredEye disorders0/1201/77
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders0/1201/77
LabyrinthitisInfections and infestations1/1200/77
Most frequent other events
Showing 10 of 19
Most frequent other events
EventInitial Treatment: Rituximab + MTXRe-treatment: Rituximab + MTX
Rheumatoid arthritisMusculoskeletal and connective tissue disorders20/1205/77
NauseaGastrointestinal disorders17/1209/77
HeadacheNervous system disorders14/1206/77
NasopharyngitisInfections and infestations13/1208/77
CoughRespiratory, thoracic and mediastinal disorders13/1202/77
FatigueGeneral disorders10/1201/77
Urinary tract infectionInfections and infestations9/1203/77
Back painMusculoskeletal and connective tissue disorders9/1203/77
DizzinessNervous system disorders9/1203/77
VomitingGastrointestinal disorders7/1205/77

Baseline characteristics

Intent-to-Treat (ITT) Population: all participants who recieved any amount of infused medication whether or not they completed any further assessment.

Age, Continuous
Age, Continuous(years)Rituximab + MTX
Mean55.6 ± 10.20
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + MTX
Female87
Male33
08

Study locations

41 sites
  • Edmonton, Alberta T5M 0H4, Canada
  • Edmonton, Alberta T6G 2B7, Canada
  • Kelowna, British Columbia V1Y 3G8, Canada
  • Vancouver, British Columbia V5Z 3Y1, Canada
  • Victoria, British Columbia V8V 3P9, Canada
  • Winnipeg, Manitoba R3A 1M4, Canada
  • St John's, Newfoundland and Labrador A1A 5E8, Canada
  • St John's, Newfoundland and Labrador A1C 5B8, Canada
  • Hamilton, Ontario L8N 1Y2, Canada
  • Hamilton, Ontario L8S 4J9, Canada
  • Mississauga, Ontario L5M 2V8, Canada
  • Nepean, Ontario K2G 6E2, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Ottawa, Ontario K1S 1C2, Canada
  • Thunder Bay, Ontario P7B 5G3, Canada
  • Toronto, Ontario M4K 1N2, Canada
  • Toronto, Ontario M5G 1X5, Canada
  • Toronto, Ontario M5T 2S8, Canada
  • Windsor, Ontario N8X 5A6, Canada
  • Laval, Quebec H7G 2E6, Canada
  • Montreal, Quebec H1T 2M4, Canada
  • Montreal, Quebec H2L 1S6, Canada
  • Montreal, Quebec H2L 4M1, Canada
  • Montreal, Quebec H3T 1E2, Canada
  • Quebec City, Quebec G1V 3M7, Canada
  • Sainte-foy, Quebec G1W 4R4, Canada
  • Sherbrooke, Quebec J1H 5N4, Canada
  • St-eustache, Quebec J7P 4J2, Canada
  • Trois-rivieres, Quebec G8Z 1Y2, Canada
  • Boras, 50182, Sweden
  • Falun, 79182, Sweden
  • Goeteborg, 41345, Sweden
  • Jonkoping, 551 85, Sweden
  • Kalmar, 39185, Sweden
  • Karlskrona, 37185, Sweden
  • Lulea, 97180, Sweden
  • Malmoe, 20502, Sweden
  • Oskarstroem, 31392, Sweden
  • Skoevde, 54185, Sweden
  • Stockholm, 18288, Sweden
  • Sundsvall, 85186, Sweden
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2006 to primary completion in Mar 2009, 31 months.

Results were first posted in Aug 2014, 5 years 4 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 31 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2011
First posted
Jan 10, 2011
StartActual
Jul 18, 2006
Primary completionActual
Mar 12, 2009
CompletionActual
Mar 12, 2009
Results first posted
Aug 5, 2014
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01272908
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 10, 2011
Start date
Jul 18, 2006
Primary completion
Mar 12, 2009
Completion
Mar 12, 2009
Results posted
Aug 5, 2014
Last update
Aug 15, 2017

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion